Novartis AG is drip-feeding data from its APPLAUSE-IgAN trial. The study, assessing the oral complement factor B inhibitor Fabhalta (iptacopan) in IgA nephropathy (IgAN), was toplined a success in October. Now the company has revealed the finding on one of the two co-primary endpoints, saying that Fabhalta-treated patients achieved a statistically significant (p<0.0001) reduction in proteinuria.
The data come from a pre-specified interim analysis comprising 250 patients for the efficacy analysis and 443 for the safety...
Welcome to Scrip
Create an account to read this article
Already a subscriber?